leadf
logo-loader
viewAstraZeneca PLC
(
LSE:AZN
)

AstraZeneca says COVID-19 vaccine effective against Delta variant

Public Health England said the jab is 92% effective against hospitalisation from the strain

AstraZeneca - AstraZeneca says COVID-19 vaccine effective against Delta variant

AstraZeneca PLC (LON:AZN) said its Coronavirus (COVID-19) vaccine developed with Oxford University is effective against the Delta and Kappa variant, which were first found in India.

The FTSE 100 cited a study by the university built on an analysis by the Public Health England (PHE), Reuters reported.

READ: AstraZeneca receives EU approval for nerve cancer therapy for kids

Last week, PHE said a full course of the AstraZeneca jab is 92% effective against hospitalisation from the strain, while the Pfizer/BioNTech vaccine offers 96% protection.

Researchers are still investigating their efficacy against death, although it is “expected to be high”, PHE said.

The analysis included 14,019 cases of the Delta variant – 166 of whom were hospitalised – between 12 April and 4 June, looking at emergency hospital admissions in England.

As of last week, the Delta variant accounted for 99% of cases in the UK, which had risen by 33,630 in a week to a total of 75,953.

Quick facts: AstraZeneca PLC

Follow
LSE:AZN

Price: 8706 GBX

Market Cap: £134.78 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Allergy Therapeutics reveal record pre-R&D operating profit with continued...

Allergy Therapeutics, Allergy Therapeutics PLC's (LON:AGY) CEO Manuel Llobet and chief financial officer Nick Wykeman join Proactive London's Katie Pilbeam about their results for the Year ended 30 June 2021.  The team explain their record pre-R&D operating profit which were ahead of...

15 minutes ago

2 min read